Slingshot members are tracking this event:
Portola Pharmaceuticals (NASDAQ: PTLA) receives Complete Response Letter (CRL) from FDA for BLA for Andexxa, an antidote for bleeding related to factor Xa inhibitors (8/17/2016).
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Aug 17, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Factor Xa Inhibitor, Frequent Bleeding Episodes